Summary of Significant Accounting Policies - Performance Obligations and Research and Development Costs (Details) - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Summary of Significant Accounting Policies | |||
| Minimum payment term | 30 days | ||
| Maximum payment term | 45 days | ||
| Practical expedient | |||
| Unsatisfied performance obligations | true | ||
| Unsatisfied performance obligations amount | $ 0.1 | ||
| Research and development costs | $ 22.0 | $ 16.6 | $ 16.7 |
| X | ||||||||||
- Definition Represents the maximum payment term. No definition available.
|
| X | ||||||||||
- Definition Represents the minimum payment term. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Indicates (true false) whether optional exemption was applied not to disclose amount of transaction price allocated to and explanation of expected timing of revenue recognition for remaining performance obligation, when contract has expected duration of one year or less or right to consideration corresponds directly to performance completed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|